Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy

CONCLUSION: Considering that the very short circulation half-life (<1 second) of plasmin prevents its systemic use but also makes it safer without off-target drug effects, clot-targeted delivery of plasmin using CTNPs can enable safer and more efficacious fibrinolytic therapy.PMID:36696210 | DOI:10.1016/j.jtha.2022.11.037

Source: Thrombosis and Haemostasis - January 25, 2023 Category: Hematology Authors: Michael Sun M Hao Hao Pontius Stephanie Yang Tejal Pendekanti Shruti Raghunathan Jordan A Shavit Anirban Sen Gupta Source Type: research